Pro­to­cols: In­di­v­ior claims PhI­II suc­cess, points to 2017 FDA OK; In­Vi­vo touts an­oth­er pa­tient re­sponse in spinal study

The UK’s In­di­v­ior (LON: IN­DV) got a boost to­day af­ter an­nounc­ing that its Phase III study of a month­ly dose of buprenor­phine was pos­i­tive. The biotech says that based on its con­ver­sa­tions with the FDA, the com­pa­ny may get a green light for this ther­a­py by the end of next year. The month­ly dos­ing is in­tend­ed to as­sist pa­tients who are be­ing treat­ed for opi­oid abuse, mak­ing a re­lapse less like­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.